Clinical bottom line
Pancreatic polypeptide (PP) cells, a lesser-studied islet cell type, are emerging as a putative target for metabolic regulation and diabetes management. Early preclinical and translational research suggests that modulating PP cell function or signaling may influence appetite regulation, hepatic glucose production, and insulin sensitivity. However, clinical evidence remains limited, and the therapeutic potential of targeting PP cells is largely hypothesis-generating at this stage. Further mechanistic and clinical studies are warranted to clarify their role and develop targeted interventions.
What the evidence shows
Pancreatic polypeptide cells, located primarily in the islet periphery, secrete pancreatic polypeptide, a hormone implicated in appetite suppression, regulation of gastric motility, and modulation of hepatic glucose output. Unlike the extensively studied beta and alpha cells, PP cells have been relatively neglected in diabetes research. Recent advances in islet cell biology and targeted delivery systems have renewed interest in their metabolic role.
Emerging molecular therapies aiming to modulate islet cell populations have focused predominantly on beta cells, as reviewed by Collins et al. (2025), who highlight nanocarrier strategies for beta cell targeting in type 1 diabetes. While these approaches do not yet extend to PP cells, they provide a framework for future cell-specific interventions.
Metabolic regulation via gut-pancreas axis hormones, including glucagon-like peptides and glucose-dependent insulinotropic polypeptide, has been extensively studied (Xu et al., 2024). PP cells may interact with these pathways indirectly, influencing energy homeostasis and insulin sensitivity. Msane et al. (2026) discuss the broader context of metabolic dysfunction and steatotic liver disease in type 2 diabetes, emphasizing the complex interplay of gut hormones, inflammation, and circadian factors, which could intersect with PP cell activity.
Preclinical data suggest that pancreatic polypeptide administration can reduce food intake and improve glucose tolerance, but human trials are sparse. The precise mechanisms by which PP cells influence hepatic glucose production and peripheral insulin sensitivity remain to be elucidated. Moreover, the heterogeneity of islet cell populations and their paracrine interactions complicate the interpretation of PP cell-specific effects.
Caveats and uncertainty
The evidence base for targeting pancreatic polypeptide cells in diabetes is currently limited and largely preclinical or exploratory. Unlike beta cells, which have well-characterized roles and established therapeutic targets, PP cells lack robust clinical trial data supporting their manipulation.
The physiological role of pancreatic polypeptide is multifaceted and context-dependent, involving central nervous system pathways and peripheral metabolic tissues. This complexity raises challenges for designing selective therapies without off-target effects.
Furthermore, current islet-targeting technologies, such as nanocarriers described by Collins et al. (2025), have not yet been adapted to PP cells, limiting translational progress. The interplay between PP cells and other islet hormones, as well as gut-derived peptides (Xu et al., 2024), requires further elucidation to avoid unintended metabolic consequences.
Finally, patient heterogeneity in diabetes phenotypes and comorbidities, including non-alcoholic fatty liver disease (Msane et al., 2026), may influence the efficacy and safety of PP cell-targeted therapies, underscoring the need for personalized approaches.
How this may change practice
While still in early stages, therapies targeting pancreatic polypeptide cells could represent a novel adjunctive approach to metabolic regulation in diabetes, complementing existing incretin-based and insulin therapies. If future studies validate the role of PP cells in appetite control and hepatic glucose metabolism, pharmacologic agents or biologics modulating PP secretion or receptor signaling might be developed.
Clinicians should remain aware of ongoing research in islet cell heterogeneity and emerging molecular therapies that extend beyond beta cells. Advances in targeted delivery systems may eventually enable precision modulation of PP cells, potentially improving glycemic control and reducing insulin resistance.
In the near term, this area remains primarily research-focused. Integration into clinical practice will depend on robust clinical trials demonstrating safety, efficacy, and patient-centered outcomes.